8:34 AM
Apr 26, 2017
 |  BC Extra  |  Clinical News

Alzheon identifies MOA for AD candidate

In a paper published in CNS Drugs, researchers from Alzheon Inc. (Framingham, Mass.) identified the mechanism of action for tramiprosate, the active agent in its Alzheimer's disease candidate ALZ-801. The paper showed that the compound inhibits beta amyloid...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >